TAT and myocardial infarction: In brief, Tat-DAXXp treatment decreased by 70% plasma cTnI concentration and mortality assessed at 24 h post-MI, and furthermore, increased ejection fraction (24%) compared to the non-treated control group during the 6-month follow-up.